All In Biotech

Drug Trial Radar · NCT06380881

PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases

A Single-center, Open-label, Single-arm Phase Ib Clinical Study to Evaluate the Pharmacokinetics and Pharmacodynamic Characteristics of SHR-2017 Injection in Patients With Bone Metastases

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

May 20, 2024

Primary completion

Aug 6, 2025

Study completion Aug 6, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics, safety, tolerability and immunogenicity of SHR-2017 injection in patients with bone metastases, and to evaluate the efficacy of SHR-2017 injection in the treatment of skeletal-related event and cancer pain.

Conditions

  • Patients With Bone Metastases

Interventions

  • SHR-2017Drug

    SHR-2017

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Pharmacokinetic parameters of SHR-2017 after administration, including CmaxTime frame: First dose up to 169 days post-dose
  2. The Pharmacokinetic parameters of SHR-2017 after administration, including TmaxTime frame: First dose up to 169 days post-dose
  3. The Pharmacokinetic parameters of SHR-2017 after administration, including AUC0-tTime frame: First dose up to 169 days post-dose
  4. The Pharmacokinetic parameters of SHR-2017 after administration, including AUC0-∞Time frame: First dose up to 169 days post-dose
  5. The Pharmacokinetic parameters of SHR-2017 after administration, including t1/2Time frame: First dose up to 169 days post-dose
  6. The Pharmacokinetic parameters of SHR-2017 after administration, including CL/FTime frame: First dose up to 169 days post-dose
  7. The pharmacodynamic parameter of SHR-2017 after administration include uNTX/uCrTime frame: First dose up to 169 days post-dose
  8. The pharmacodynamic parameter of SHR-2017 after administration include β-CTXTime frame: First dose up to 169 days post-dose
  9. The pharmacodynamic parameter of SHR-2017 after administration include BALP [TimeTime frame: First dose up to 169 days post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.